This is a humanized IgG4 antibody using the same sequences as the therapeutic antibody ixekizumab. It specifically targets interleukin-17A (IL17A) and prevents its interaction with the IL17A receptor. Given that IL17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its activity holds significant therapeutic potential for inflammatory conditions. Notably, IL17A stimulates proliferation and activation of keratinocytes in the skin. Ixekizumab is indicated for treating patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Additionally, it is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis accompanied by objective signs of inflammation.